This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mixed Chimeric Transplantation for Primary Amyloidosis

This study has been withdrawn prior to enrollment.
(Closed, never started.)
Information provided by:
Stanford University Identifier:
First received: September 13, 2005
Last updated: October 5, 2007
Last verified: October 2007
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Condition Intervention
Amyloidosis Procedure: autologous followed by nonmyeloablative allogeneic transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures:
  • Toxicity of therapy
  • Changes in marrow and serum abnormalities
  • Improvement in end-organ function.

Estimated Enrollment: 45
Study Start Date: December 2000
Estimated Study Completion Date: September 2006

Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary amyloidosis
  • adequate organ function
  • matched sibling donor

Exclusion Criteria:

  • evidence of multiple myeloma
  • HIV positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186095

Sponsors and Collaborators
Stanford University
Principal Investigator: Keith Stockerl-Goldstein, MD Stanford University
  More Information Identifier: NCT00186095     History of Changes
Other Study ID Numbers: BMT129
Study First Received: September 13, 2005
Last Updated: October 5, 2007

Keywords provided by Stanford University:
cell transplantation

Additional relevant MeSH terms:
Proteostasis Deficiencies
Metabolic Diseases processed this record on September 21, 2017